BioVie Inc. has presented its latest corporate update, highlighting the development of its lead asset, bezisterim (formerly NE3107). This small, orally bioavailable molecule has shown promise in clinical trials by modulating TNF_α_ production, which has led to reduced inflammation and insulin resistance. Patients with Parkinson's disease $(PD)$ have experienced improved motor control and "morning on" symptoms, while those with Alzheimer's Disease (AD) have shown improved cognition and function, along with lowered amyloid β and p-tau levels. The company is currently enrolling patients for a Parkinson's Phase 2b trial and a Long Covid exploratory Phase 2 trial. Additionally, BioVie is focused on advancing a therapeutic for ascites, a condition with a high mortality rate, and has plans for future trials in Alzheimer's and ascites pending funding and partnerships. The presentation also notes that bezisterim has crossed the blood-brain barrier, indicating both CNS and peripheral applications, with no safety issues identified thus far in pre-clinical and clinical trials. You can access the full presentation through the link below.